Arterial and venous thromboembolism is a major medical concern that requires therapeutic anticoagulation in various medical fields to prevent its drastic consequences. Despite significant advances in anticoagulant therapy, thrombosis remains a …
The use of intravenous antiplatelet therapy during primary percutaneous coronary intervention (PPCI) is not fully standardized. The aim is to evaluate the effectiveness and safety of periprocedural intravenous administration of cangrelor or …
verfasst von:
Angelo Silverio, Michele Bellino, Fernando Scudiero, Tiziana Attisano, Cesare Baldi, Angelo Catalano, Mario Centore, Arturo Cesaro, Marco Di Maio, Luca Esposito, Giovanni Granata, Francesco Maiellaro, Iacopo Muraca, Giuseppe Musumeci, Guido Parodi, Davide Personeni, Renato Valenti, Carmine Vecchione, Paolo Calabrò, Gennaro Galasso
Non-activated four-factor prothrombin complex concentrate (4 F-PCC) has emerged as the preferred reversal strategy for patients on warfarin with life-threatening bleeding. Current dosing recommendations for 4 F-PCC require pre-treatment …
verfasst von:
Meghan E. Peterson, Megan P. Jaynes, Sarah Berardi, Colleen Morton
Venous thromboembolism (VTE) and stroke carry significant mortality and morbidity in cancer patients. Direct oral anticoagulants (DOACs) have been demonstrated to be effective for the treatment of VTE and prevention of stroke in atrial …
verfasst von:
Sophia Lee, Jeremy A. Ross, Ali Zalpour, Jason T. Henry, Cristhiam M. Rojas Hernandez
Although low-dose direct oral anticoagulants (DOACs) are recommended for patients at high risk of bleeding complications, it remains unclear whether the dose reduction in real-world setting is also appropriate in patients after large-vessel …
Anticoagulation in patients with mechanical heart valves (MHV) is associated with a risk of major bleeding episodes (MBE). In case of MBE, anticoagulant interruption is advocated. However, there is lack of data regarding the thrombo-embolic events …
verfasst von:
Pascal Augustin, Stefan Andrei, Bernard Iung, Marylou Para, Peter Matthews, Christian de Tymowski, Nadine Ajzenberg, Philippe Montravers
Low-dose prasugrel demonstrated a similar effectiveness profile to clopidogrel in East Asian ACS patients, but its comparison with another new-generation potent P2Y12 inhibitor, ticagrelor, remains unclear. To compare the effectiveness and safety …
Blood flow disorders are often the result of the non-physiological narrowing of blood arteries caused by atherosclerosis and thrombus. The blood then proceeds through rising-peak-decreasing phases as it passes through the narrow area. Although …
verfasst von:
Xuemei Gao, Tiancong Zhang, Xiaojing Huang, Xuanrong Huan, Yuan Li
Moderate-strong CYP3A4 or Pgp inhibitors and inducers alter direct oral anticoagulant (DOAC) pharmacokinetics. Whether the presence of a DOAC drug-drug interaction (DDI) prompts in- hospital changes in management remains unknown. We identified all …
verfasst von:
Mohsen H. Al Zaria, Leo F. Buckley, Heather Dell’orfano, Peter Manzo, John Fanikos
Vaccines against SARS-CoV-2 have been recommended across the world, yet no study has investigated whether COVID-19 vaccination influences short-term warfarin anti-coagulation levels. Patients on stable warfarin treatment who received …
verfasst von:
Li-Hua Liu, Yang-Zhao Zhou, Tian-Yu Li, Da-Bin Kuang, Qun Liang, Lei Chen, Da-Feng Yang, Xia Zhang, Sheng-Lan Tan
Hypercoagulability and reduced fibrinolysis are well-established complications associated with COVID-19. However, the timelines for the onset and resolution of these complications remain unclear. The aim of this study was to evaluate, in a cohort …
verfasst von:
Erica Okazaki, Bárbara Gomes Barion, Tania Rubia Flores da Rocha, Giovanna Di Giacomo, Yeh-Li Ho, Cynthia Rothschild, Giancarlo Fatobene, Bruna del Guerra de Carvalho Moraes, Bianca Stefanello, Paula Ribeiro Villaça, Vanderson Geraldo Rocha, Fernanda Andrade Orsi
Oral anticoagulants (OACs) are recommended for patients with atrial fibrillation (AFib) having CHA2DS2-VASc score ≥ 2. However, the benefits of OAC initiation in patients with AFib and cancer at different levels of CHA2DS2-VASc is unknown. We …
verfasst von:
Bang Truong, Lori Hornsby, Brent Fox, Chiahung Chou, Jingyi Zheng, Jingjing Qian
Coronary artery bypass graft (CABG) procedures face challenges related to graft failure, driven by factors such as acute thrombosis, neointimal hyperplasia, and atherosclerotic plaque formation. Despite extensive efforts over four decades, the …
verfasst von:
Maria Sara Mauro, Simone Finocchiaro, Dario Calderone, Carla Rochira, Federica Agnello, Lorenzo Scalia, Davide Capodanno
While direct oral anticoagulants (DOACs) are frequently used to treat venous thromboembolism (VTE), the outcomes of patients with inherited thrombophilia (IT) receiving DOACs for VTE remain understudied. We used data from the international RIETE …
verfasst von:
Omri Cohen, Gili Kenet, Sarina Levy-Mendelovich, Inna Tzoran, Benjamin Brenner, Cristina De Ancos, Patricia López-Miguel, José F. Varona, Judith Catella, Manuel Monreal, and the RIETE investigators
Superficial vein thrombosis (SVT) has been traditionally perceived as a benign condition within the spectrum of venous thromboembolism (VTE), distinct from deep vein thrombosis (DVT) and pulmonary embolism (PE) in terms of its clinical …
verfasst von:
Alejandro Díez-Vidal, Javier Gómez López, Pablo Rodríguez Fuertes, Fabián Tejeda Jurado, Paula Berrocal Espinosa, Juan Francisco Martínez Ballester, Sonia Rodríguez Roca, María Angélica Rivera Núñez, Ana María Martínez Virto, Yale Tung-Chen
Optimal risk stratification of patients with cancer and pulmonary embolism (PE) remains unclear. We constructed a clinical prediction rule (CPR) named ‘MAUPE-C’ to identify patients with low 30 days mortality. The study retrospectively developed …
verfasst von:
Mario Aramberri, Jesús González-Olmedo, Adrián García-Villa, Ane Villanueva, Cristina Castillo Maza, Susana García-Gutiérrez, Carmen Diaz-Pedroche
Vitamin K antagonists (VKA) is the primary anticoagulant in most settings of Sub-Saharan Africa. Understanding the quality of anticoagulation services in the continent is vital in optimising the intended benefits. This study assessed the quality …
verfasst von:
Julius Chacha Mwita, Joel Msafiri Francis, Chriselda Pillay, Okechukwu S. Ogah, Dejuma Yadeta Goshu, Francis Agyekum, John Mukuka Musonda, Maduka Chiedozie James, Endale Tefera, Tsie Kabo, Keolebile Irene Ditlhabolo, Kagiso Ndlovu, Ayoola Yekeen Ayodele, Wigilya P. Mkomanga, Pilly Chillo, Albertino Damasceno, Aba Ankomaba Folson, Anthony Oyekunle, Erius Tebuka, Fredrick Kalokola, Karen Forrest, Helena Dunn, Kamilu Karaye, Fina Lubaki Jean-Pierre, Chala Fekadu Oljira, Tamirat Assefa Tadesse, Tolulope Shogade Taiwo, Chibuike E. Nwafor, Olufemi Omole, Raphael Anakwue, Karen Cohen
Genotype based personalized antiplatelet therapy in the setting of percutaneous coronary intervention (PCI) has been studied in clinical trials. Despite the demonstrated risk associated with CYP2C19 loss-of-function (LoF) carriage in …
verfasst von:
Paul A. Gurbel, Kevin Bliden, Matthew Sherwood, Hamid Taheri, Behnam Tehrani, Marjaneh Akbari, Shahram Yazdani, Juzer Ali Asgar, Rahul Chaudhary, Udaya S. Tantry
Cancer-associated venous thromboembolism (VTE) is a common complication and a leading cause of morbidity and mortality in cancer patients [ 1 ]. Patients with cancer have more than a 4-to-6-fold risk of VTE compared to the general population [ 2 ] …
In managing cerebral venous sinus thrombosis (CVT), the standard approach has been administering parenteral anticoagulation for at least five days, despite limited supporting evidence. This study aimed to determine the optimal duration of …
verfasst von:
Ariel N. Carrion, Teresa A. Allison, Sophie Samuel
